TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06141681

Intervention type: OTHER
Intervention: photoplethysmography
Description: Photoplethysmography (BluePoint, Frankfurt, Germany) is the pulse wave measured by a pulse oximeter. It is obtained based on the absorbance of red/infrared light in a given tissue. The signal is made up of two components: 1) the alternating component (AC), which is the pulse wave itself, which is determined by the absorbance of pulsatile arterial blood. 2) The continuous component (DC), which represents the absorbance of venous blood and the rest of the tissues. Within these tests the investigators find vascular occlusion, elevation of the legs, raising or lowering the tested hand above/below the phlebostatic level, cold/heat test, etc. Each of them evaluates different aspects of circulation such as endothelial function, myogenic response to blood flow, perfusion pressure, autonomic reflexes, preload-dependence, or venous flow among other aspects of microcirculation.

Intervention type: OTHER
Intervention: photoplethysmography
Description: Photoplethysmography (BluePoint, Frankfurt, Germany) is the pulse wave measured by a pulse oximeter. It is obtained based on the absorbance of red/infrared light in a given tissue. The signal is made up of two components: 1) the alternating component (AC), which is the pulse wave itself, which is determined by the absorbance of pulsatile arterial blood. 2) The continuous component (DC), which represents the absorbance of venous blood and the rest of the tissues. Within these tests the investigators find vascular occlusion, elevation of the legs, raising or lowering the tested hand above/below the phlebostatic level, cold/heat test, etc. Each of them evaluates different aspects of circulation such as endothelial function, myogenic response to blood flow, perfusion pressure, autonomic reflexes, preload-dependence, or venous flow among other aspects of microcirculation.

Intervention type: OTHER
Intervention: photoplethysmography
Description: Photoplethysmography (BluePoint, Frankfurt, Germany) is the pulse wave measured by a pulse oximeter. It is obtained based on the absorbance of red/infrared light in a given tissue. The signal is made up of two components: 1) the alternating component (AC), which is the pulse wave itself, which is determined by the absorbance of pulsatile arterial blood. 2) The continuous component (DC), which represents the absorbance of venous blood and the rest of the tissues. Within these tests the investigators find vascular occlusion, elevation of the legs, raising or lowering the tested hand above/below the phlebostatic level, cold/heat test, etc. Each of them evaluates different aspects of circulation such as endothelial function, myogenic response to blood flow, perfusion pressure, autonomic reflexes, preload-dependence, or venous flow among other aspects of microcirculation.
Study: NCT05062772

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Description: Intraoperative ultrasound imaging
Study: NCT05504421

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sustainability education in nursing to be given with two different teaching methods
Description: Sustainability education in nursing to be given with two different teaching methods (cooperative learning versus traditional learning) and the effects of two different teaching methods on the sustainability knowledge, attitude and skill acquisition of nursing students will be compared.
Study: NCT05275699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-FAPI
Description: Intravenous injection of one dosage of 18.5-22.2MBq (0.5-0.6 mCi)/Kg 68Ga-FAPI. Tracer doses of 68Ga-FAPI will be used to image lesions of keloid by PET/CT.
Study: NCT05579548

Intervention type: DRUG
Intervention: Pegvaliase
Description: Pregnant women exposed to pegvaliase within 2 weeks prior to LMP.
Study: NCT05504421

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sustainability education in nursing to be given with two different teaching methods
Description: Sustainability education in nursing to be given with two different teaching methods (cooperative learning versus traditional learning) and the effects of two different teaching methods on the sustainability knowledge, attitude and skill acquisition of nursing students will be compared.
Study: NCT05200494

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Recruiting Maneuver
Description: Airway pressure will be increased to 30 cmH2O for 30 seconds at the end of the bronchoscopy
Study: NCT06281301

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: education tool
Description: Participants will have 15 minutes to review the single sided card and then the survey will be administered. Participants will then be surveyed again within 1-2 weeks after initial completion to assess how well information was retained.

Intervention type: OTHER
Group type: OTHER
Intervention: no additional information
Description: Survey will be administered without reviewing the single sided card
Study: NCT04727281

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality of life assessment using the Kidney Disease Quality of Life 36 (KDQOL-36) short form and Malnutrition-Inflammation Score
Description: Data about nutritional status using the Malnutrition-Inflammation Score, and Quality of life assessment using the Kidney Disease Quality of Life 36 (KDQOL-36) short form. Dialysis related data, The time needed for the patient to recover from a dialysis session (in minutes), Detailed history taking, Thorough physical examination, Laboratory Investigations:~• Hemoglobin , Serum sodium and potassium , Serum creatinine and blood urea , Serum phosphorus, serum calcium , Serum PTH level , Serum albumin ,CRP ,Total iron-binding capacity .
Study: NCT06453876

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound assisted Thrombolysis
Description: Please see Arms
Study: NCT06052566

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efinopegdutide
Description: Subcutaneous injection administered at a dose of 7 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efinopegdutide
Description: Subcutaneous injection administered at a dose of 7 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efinopegdutide
Description: Subcutaneous injection administered at a dose of 7 mg
Study: NCT06014385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Scopolamine
Description: TO will be measured following a 15-minute IV infusion of up to 2 dose levels of scopolamine: 4.0 μg/kg and 2.0 μg/kg
Study: NCT06453876

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Embolectomy
Description: Please see arms

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin
Description: Active comparator
Study: NCT04972175

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 50-Hour Intervention - Rapid Insulin lispro
Description: Subcutaneous-delivery of insulin lispro using pump therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50-Hour Intervention - BC LisPram
Description: Subcutaneous-delivery of BC LisPram using pump therapy.
Study: NCT04972175

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50-Hour Intervention - BC LisPram
Description: Subcutaneous-delivery of BC LisPram using pump therapy.
Study: NCT06014385

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [11C]EMO ([11C]LSN3172176)
Description: A radiotracer specific for imaging M1 receptors. For each PET scan, up to 20 mCi of \[11C\]EMO i.v. will be administered twice, at baseline and post dosing with scopolamine.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [11C]EMO ([11C]LSN3172176)
Description: A radiotracer specific for imaging M1 receptors. For each PET scan, up to 20 mCi of \[11C\]EMO i.v. will be administered twice, at baseline and post dosing with scopolamine.
Study: NCT04276701

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood sample
Description: 35 ml whole blood for Peripheral blood mononuclear cell (PBMC), serum and plasma

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasonography assessment
Description: assessment of atherosclerotic plaques and measurement of carotid intima-media thickness (cIMT)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: questionnaires
Description: Food and exercise questionnaires validated by the American heart Association
Study: NCT05954104

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcipotriol
Description: To evaluate the efficacy of Calcipotriol on Alopecia Areata.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcipotriol
Description: To evaluate the efficacy of Calcipotriol on Alopecia Areata.
Study: NCT06183125

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine-based program
Description: Week1-2: one health talk session(60 mins); three workshops (each workshop will last for 60-90mins) to provide hands-on training in Baduanjin, acupressure techniques, mindful stretching, and effective strategies to combat sedentary behavior in the workplace.~Week 3-4: group practice sessions will take place for one hour every other day throughout the workweek; website support.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Traditional Chinese Medicine-based program
Description: Week1-2: one health talk session(60 mins); three workshops (each workshop will last for 60-90mins) to provide hands-on training in Baduanjin, acupressure techniques, mindful stretching, and effective strategies to combat sedentary behavior in the workplace.~Week 3-4: group practice sessions will take place for one hour every other day throughout the workweek; website support.
Study: NCT05111964

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Intensity Focused Ultrasound Ablation
Description: The focused ultrasound exposure will be performed using the Haifu® Model-JC200 Focused Ultrasound Tumour Therapeutic System at the Churchill Hospital site, CE-approved for tumour therapy (or subsequent CE-approved device upgrades by Haifu®). The participant will be positioned over the therapeutic device and water bath used to transmit the focused ultrasound to the target tumour. No anaesthesia or any combination of local anaesthesia, nerve block, epidural, conscious sedation or general anaesthetic may be used, depending on anatomical location, size of tumour, preference of HIFU team, patient and anaesthetist and other patient factors.~In therapy mode, the tumour volume is treated with focused ultrasound to ablate the tumour tissues to high temperatures (in excess of 60ºC) using focused ultrasound targeted from outside the body.~Patients are typically discharged with 24 hours.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Tumour Biopsy and Venous Blood Tests
Description: Where appropriate, participants are also encouraged to undergo a pre-HIFU (and in the case of unresectable STS, post-HIFU) ultrasound biopsy of the target tumour and additional blood tests to inform the immunological aspects of the study. Having the biopsy does not mandate enrolment on the trial, and patients will be free to leave the trial at any stage. The pre-HIFU (and post-HIFU) biopsies are altruistically encouraged but not absolutely essential to enrolment on the trial.~Biopsies will be performed under ultrasound guidance by an experienced radiologist using local anaesthetic.
Study: NCT06034314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dronabinol Capsules
Description: Two 10 mg Dronabinol capsules will be administered orally, for a total of 20mg, on test day.
Study: NCT05554003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide capsule
Description: Metronomic temozolomide 60 mg/die continuously
Study: NCT05135312

Intervention type: DRUG
Group type: OTHER
Intervention: Etanercept
Description: TNF-alpha inhibitors improve nail psoriasis.
Study: NCT05755113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tigilanol Tiglate
Description: Tigilanol tiglate is a novel, short-chain diterpene ester in clinical development for intratumoural treatment of a wide range of solid tumours.
Study: NCT04515719

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Belimumab
Description: Belimumab 2mg/kg intravenously

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo intravenously
Study: NCT05173350

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RETAIN KY
Description: The experimental group receives a combination of medical provider services, stay-at-work (SAW)/return-to-work (RTW) coordination services, and other SAW/RTW services. Services offered by the project include individualized intensive vocational services from RETAIN RTW Coordinators, with an emphasis on assistive technology, universal design, and peer support. The project provides training on SAW/RTW best practices and RETAIN, as well as financial incentives to health care professionals. The treatment group is eligible to receive the full set of RETAIN intervention activities.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator
Description: Those in the active comparator arm continue to receive medical services. A RTW coordinator creates a RTW plan with the enrollee and refers them to existing resources. The RTW coordinator works with enrollees for 2.5 hours total.
Study: NCT05135312

Intervention type: DEVICE
Group type: OTHER
Intervention: OCT
Description: Optical Coherence Tomography is a noninvasive imaging device that can be used to monitor nail disease severity.
Study: NCT05463601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mecapegfilgrastim
Description: Mecapegfilgrastim

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dalpiciclib
Description: dalpiciclib

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dalpiciclib
Description: dalpiciclib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exemestane, fulvestrant, letrozole, tamoxifen
Description: endocrine therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: exemestane, fulvestrant, letrozole, tamoxifen
Description: endocrine therapy
Study: NCT05869084

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: pulmonary function tests
Description: pulmonary function tests
Study: NCT05930704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-2017 injection
Description: Randomized participants of multiple dose cohorts will receive a single subcutaneous dose of SHR-2017 injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Randomized participants will receive a single SC injection dose of matching placebo.
Study: NCT05672004

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PUMP-fit strategy (implementation toolbox)
Description: Healthcare professionals will receive the ProMuscle training from one of the researchers during a one-hour online meeting (during the control period).~Healthcare professionals will be informed about the platform and toolbox. Healthcare professionals receive a personal log-in for the online platform. Healthcare professionals receive a questionnaire about their readiness for implementation. The results of this questionnaire are directly visible on the platform Within the separate environment of the online platform, healthcare professionals can access their implementation toolbox. The toolbox is tailored to their personal context based on the results of the 'Readinesstool'.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Implementation as usual
Description: First, healthcare professionals will receive the ProMuscle training from one of the researchers during a one-hour online meeting.~At the end of the training healthcare professionals are informed about the mandatory conditions to implement ProMuscle (champion, material, approval of management).~Healthcare professionals receive a questionnaire about their readiness for implementation. The results of this questionnaire are directly visible. Results contain a graph of possible barriers for implementation in their practice.~Hereafter they will be instructed to start with implementation as usual.
Study: NCT06409663

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NVX-CoV2705 Vaccine
Description: All injections will be administered in a 0.5 mL injection volume at an antigenic dose of 5 µg with 50 µg Matrix-M adjuvant at each injection.
Study: NCT05312216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab plus Lenvatinib
Description: Durvalumab: 1500mg, iv.drip, Q4w Lenvatinib: 8mg, QD (body weight \< 60kg) or 12mg, QD (body weight ≥ 60kg)~Number of cycle: until subjects withdrawing the informed consent OR progressive disease OR developing unacceptable toxicity events
Study: NCT04640129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-Interferon Alfa, Tenofovir Disoproxil Fumarate
Description: Combination therapy group was treated with PEG-interferon Alfa in addition to TDF monotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir Disoproxil Fumarate
Description: TDF monotherapy
Study: NCT05444296

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Superficial Dry Needling
Description: 1/2 needles will placed into defined innervation fields of the trigeminal nerve and rotated. Total time will be 5-7 minutes.
Study: NCT05423717

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daridorexant 10 mg
Description: Daridorexant will be taken orally, once daily in the evening during the treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daridorexant 25 mg
Description: Daridorexant will be taken orally, once daily in the evening during the treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daridorexant 50 mg
Description: Daridorexant will be taken orally, once daily in the evening during the treatment period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be taken orally, once daily in the evening during the treatment period.
Study: NCT06191159

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Scalpel and standard electrocautery or PEAK PlasmaBlade
Description: Scalpel followed by completion of surgery with standard electrocautery or PEAK PlasmaBlade.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEAK PlasmaBlade
Description: PEAK PlasmaBlade for entire surgery.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard Electrocautery
Description: Standard Electrocautery for entire surgery.
Study: NCT05797740

Intervention type: DRUG
Intervention: Mavenclad
Description: This is an observational study, participants who received cladribine tablets in routine clinical practice following the SmPC will be included.
Study: NCT05444296

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-thrust Mobilizations only
Description: Non-thrust mobilizations to be applied to the most symptomatic level of the upper cervical spine as determined by a treating physical therapist. The mobilization technique will be applied for 3 bouts of 30 seconds.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-thrust Mobilizations only
Description: Non-thrust mobilizations to be applied to the most symptomatic level of the upper cervical spine as determined by a treating physical therapist. The mobilization technique will be applied for 3 bouts of 30 seconds.
Study: NCT06626542

Intervention type: OTHER
Group type: OTHER
Intervention: resistance and aerobic training exercises
Description: resistance and aerobic training exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: resistance and aerobic training exercises
Description: resistance and aerobic training exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: resistance and aerobic training exercises
Description: resistance and aerobic training exercises
Study: NCT06430632

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic Gait Training
Description: Participants will complete standing and walking activities while wearing a robotic exoskeleton. Participants will also be asked to complete questionnaires about their walking and function.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care Gait Training
Description: Participants will complete standing and walking activities such as body weight-supported treadmill training and conventional overground walking. Participants will also be asked to complete questionnaires about their walking and function.
Study: NCT04899466

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ActiGraft
Description: Whole blood clot (WBC) gel
Study: NCT06389695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-NYM032 injection
Description: The radiation dose is about 3-6 mCi for a single patient.Using a syringe to withdraw 68Ga-NYM032 injection, the dose will be administered via an intravenous injection and the injection time will be about 45-60 seconds.
Study: NCT05236465

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A 3-day course
Description: The course is built on the LP manual (Parker, 2013) and includes stress theory, Positive Psychology and knowledge about regulating thoughts, feelings and behavior, and through that positively influencing physiology.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Waiting list
Description: Treatment as usual (TAU) in the first 10 weeks. After 10 weeks: Behavioural: A 3-day course. The course is built on the LP manual (Parker, 2013) and includes stress theory, Positive Psychology and knowledge about regulating thoughts, feelings and behavior, and through that positively influencing physiology.
Study: NCT06581666

Intervention type: OTHER
Intervention: No special intervention, all participants will be asked to complete same set of questionnaire.
Description: No special intervention, all participants will be asked to complete same set of questionnaire.

Intervention type: OTHER
Intervention: No special intervention, all participants will be asked to complete same set of questionnaire.
Description: No special intervention, all participants will be asked to complete same set of questionnaire.
Study: NCT06265610

Intervention type: PROCEDURE
Intervention: TIVA/TCI
Description: : The aim of this study was to evaluate the effects of total intravenous anesthesia with target-controlled infusion (TCI/TIVA) on intraoperative hemodynamic parameters and postoperative awakening criteria in pediatric endovascular intervention patients